Hanmi creates lineup with Amosartan family, challenging annul KRW 100 million sales

Published: 2017-07-26 15:42:00

Updated: 2017-07-26 15:42:00

Hanmi Pharm(CEO Jong-Soo Woo, Sae-Chang Kwon) acquired approvals for 2 products of 2-substance combination drug containing the substance of Amosartan, the top sales product. Hanmi is planning to continue the Amosartan wave with 3 products of the ‘Amosartan family’ in the antihypertensive market.

Hanmi Pharm acquired commercialization approvals of ‘Amosartan Plus’ which combined ‘chlortalidone,...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.